Evaluation of a prediction model for the development of atrial fibrillation in a repository of electronic medical records

JAMA Cardiology

Volumn 1, Issue 9, 2016, Pages 1007-1013

  Kolek, Matthew J ^a   Graves, Amy J ^a   Xu, Meng ^a   Bian, Aihua ^a   Teixeira, Pedro Luis ^a   Shoemaker, M Benjamin ^a   Parvez, Babar ^a   Xu, Hua ^b   Heckbert, Susan R ^c   Ellinor, Patrick T ^d   Benjamin, Emelia J ^e,f   Alonso, Alvaro ^g   Denny, Joshua C ^a   Moons, Karel G M ^a,h   Shintani, Ayumi K ⁱ   Harrell, Frank E ^a   Roden, Dan M ^a   Darbar, Dawood ^a,j  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e FRAMINGHAM HEART STUDY   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY   (United States)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ OSAKA UNIVERSITY   (Japan)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BODY HEIGHT; BODY WEIGHT; CALIBRATION; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL HISTORY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PR INTERVAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RACE; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; TENNESSEE;

EID: 85019608042     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.3366     Document Type: Article

References (50)

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-847.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285 (18):2370-2375.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125.
4. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14(6):666-672.
5. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501.
6. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113 (5):359-364.
7. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5): 476-484.
8. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.
9. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158(3):229-234.
10. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol. 1994;74(8):826-829.
11. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J. 2004;147(1):121-126.
12. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313-320.
13. De Caterina R, Husted S, Wallentin L, et al; Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012;59(16):1413-1425.
14. Calkins H. Catheter ablation to maintain sinus rhythm. Circulation. 2012;125(11):1439-1445.
15. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129 (4):687-702.
16. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263-276.
17. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4(4):518-525.
18. Harris TB, Launer LJ, Eiriksdottir G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol. 2007;165(9):1076-1087.
19. Hofman A, Breteler MMB, van Duijn CM, et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol. 2009;24(9):553-572.
20. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation. 2009;119(4):606-618.
21. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102.
22. Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models, II: external validation, model updating, and impact assessment. Heart. 2012;98 (9):691-698.
23. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84(3):362-369.
24. Schildcrout JS, Denny JC, Bowton E, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92(2): 235-242.
25. Ritchie MD, Denny JC, Crawford DC, et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am J Hum Genet. 2010; 86(4):560-572.
26. Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc. 2013;20(e1):e147-e154.
27. Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc. 2012;19(2):212-218.
28. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR, Denny JC. MedEx: a medication information extraction system for clinical narratives. J Am Med Inform Assoc. 2010;17(1):19-24.
29. Doan S, Bastarache L, Klimkowski S, Denny JC, Xu H. Integrating existing natural language processing tools for medication extraction from discharge summaries. J Am Med Inform Assoc. 2010;17(5):528-531.
30. Liu M, Shah A, Jiang M, et al. A study of transportability of an existing smoking status detection module across institutions. AMIA Annu Symp Proc. 2012;2012:577-586.
31. Horton NJ, Kleinman KP. Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models. Am Stat. 2007;61(1):79-90.
32. Spiegelhalter DJ. Probabilistic prediction in patient management and clinical trials. Stat Med. 1986;5(5):421-433.
33. Alonso A, Roetker NS, Soliman EZ, Chen LY, Greenland P, Heckbert SR. Prediction of atrial fibrillation in a racially diverse cohort: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc. 2016;5(2):pii:e003077.
34. Pfister R, Brägelmann J, Michels G, Wareham NJ, Luben R, Khaw KT. Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort. Eur J Prev Cardiol. 2015;22(7):932-939.
35. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033-1041.
36. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease: six year follow-up experience: the Framingham Study. Ann Intern Med. 1961;55:33-50.
37. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342(13):905-912.
38. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241(19):2035-2038.
39. Kannel WB, LeBauer EJ, Dawber TR, McNamara PM. Relation of body weight to development of coronary heart disease: the Framingham Study. Circulation. 1967;35(4):734-744.
40. Allen Maycock CA, Muhlestein JB, Horne BD, et al; Intermountain Heart Collaborative Study. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002;40(10):1777-1785.
41. Emdin CA, Rahimi K, Patel A. Lowering blood pressure in patients with diabetes—reply. JAMA. 2015;313(21):2183-2184.
42. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308(6925):367-372.
43. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
44. Pedersen TR, Kjekshus J, Berg K, et al; Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004;5(3):81-87.
45. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
46. Gibbons GH. Department of Health and Human Services. National Institutes of Health. Fiscal Year 2014 Budget Request. https://officeofbudget.od.nih.gov/pdfs/FY14/2014 _Overall%20Appropriations.pdf. 2013. Accessed January 31, 2016.
47. Peterson JF, Bowton E, Field JR, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med. 2013;15(10):833-841.
48. Zhang Y, Zhang P, Mu Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2010;88(4):521-531.
49. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol. 2010;55(21): 2299-2307.
50. Hill ME, Rosenwaike I. The Social Security Administration’s Death Master File: the completeness of death reporting at older ages. Soc Secur Bull. 2001-2002/2002;64(1):45-51.